CA2529317A1 - Supplement for restoring growth hormone levels - Google Patents
Supplement for restoring growth hormone levels Download PDFInfo
- Publication number
- CA2529317A1 CA2529317A1 CA002529317A CA2529317A CA2529317A1 CA 2529317 A1 CA2529317 A1 CA 2529317A1 CA 002529317 A CA002529317 A CA 002529317A CA 2529317 A CA2529317 A CA 2529317A CA 2529317 A1 CA2529317 A1 CA 2529317A1
- Authority
- CA
- Canada
- Prior art keywords
- supplement
- amino acids
- formulation
- suitably selected
- mass range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013589 supplement Substances 0.000 title claims abstract description 154
- 239000000122 growth hormone Substances 0.000 title claims abstract description 34
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 33
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 33
- 150000001413 amino acids Chemical class 0.000 claims abstract description 84
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 46
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 39
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 32
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 30
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 28
- 239000004475 Arginine Substances 0.000 claims abstract description 26
- 239000004472 Lysine Substances 0.000 claims abstract description 26
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960002743 glutamine Drugs 0.000 claims abstract description 26
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960003104 ornithine Drugs 0.000 claims abstract description 25
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 23
- 229930182817 methionine Natural products 0.000 claims abstract description 23
- 229960004452 methionine Drugs 0.000 claims abstract description 23
- 229960003121 arginine Drugs 0.000 claims abstract description 22
- 239000004471 Glycine Substances 0.000 claims abstract description 21
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 21
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 21
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 21
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960003646 lysine Drugs 0.000 claims abstract description 20
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002775 capsule Substances 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 230000000699 topical effect Effects 0.000 claims abstract description 19
- 229960004203 carnitine Drugs 0.000 claims abstract description 18
- 229960002449 glycine Drugs 0.000 claims abstract description 7
- 235000001014 amino acid Nutrition 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 57
- 238000009472 formulation Methods 0.000 claims description 53
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 31
- 235000009697 arginine Nutrition 0.000 claims description 25
- 235000006109 methionine Nutrition 0.000 claims description 22
- 235000015872 dietary supplement Nutrition 0.000 claims description 21
- 235000004554 glutamine Nutrition 0.000 claims description 20
- 235000018977 lysine Nutrition 0.000 claims description 19
- 239000006071 cream Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002674 ointment Substances 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 13
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 12
- 229940093740 amino acid and derivative Drugs 0.000 claims description 9
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 235000019766 L-Lysine Nutrition 0.000 claims description 6
- 230000009469 supplementation Effects 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- 229930182816 L-glutamine Natural products 0.000 claims description 5
- 229930195722 L-methionine Natural products 0.000 claims description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 4
- 239000004470 DL Methionine Substances 0.000 claims description 4
- 229960001009 acetylcarnitine Drugs 0.000 claims description 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 abstract description 61
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 239000000725 suspension Substances 0.000 abstract description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000001965 increasing effect Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 102000002265 Human Growth Hormone Human genes 0.000 description 12
- 108010000521 Human Growth Hormone Proteins 0.000 description 12
- 239000000854 Human Growth Hormone Substances 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 9
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 9
- 230000000580 secretagogue effect Effects 0.000 description 9
- 230000003028 elevating effect Effects 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 102000005157 Somatostatin Human genes 0.000 description 7
- 108010056088 Somatostatin Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 7
- 229960000553 somatostatin Drugs 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 5
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 5
- 101710142969 Somatoliberin Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004198 anterior pituitary gland Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000003635 pituitary gland Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- -1 amino acid salts Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010018265 Gigantism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 206010072742 Late onset hypogonadism syndrome Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940086761 arginine 500 mg Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940026527 glycine 50 mg Drugs 0.000 description 1
- 238000009578 growth hormone therapy Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940080800 lysine 500 mg Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940099459 n-acetylmethionine Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A supplement for humans and animals for helping restore the growth hormone levels. The supplement has antioxidant protection with a combination of amino acids chosen from the group arginine, lysine, ornithine, glutamine, carnitine, glycine, methionine and N-acetyl-cysteine. The supplement is provided as a tablet, a capsule, a liquid, whether a suspension or a solution, and for topical application.
Description
SUPPLEMENT FOR RESTORING GROWTH HORMONE LEVELS
Inventor: Donald Murdoch McLeod, Merritt (CA) SUPPLEMENT FOR RESTORING GROWTH HORMONE LEVELS
FIELD OF THE INVENTION
This invention relates to the field of health supplements, including supplements which elevate release of human growth hormone and prevent oxidative damage, when applied as a cream, when taken orally as a liquid or when taken as a caspule or tablet.
BACKGROUND OF THE INVENTION
Until recently human growth hormone (hereinafter alternatively referred to as hGH) was available only in expensive injectable forms and benefits from the restoration of hGH
levels available only to those with the ability to pay. Most recently natural substances which can trigger the release of human growth hormone from an individual's own anterior pituitary gland have become available. These are generically referred to as secretagogues. Secretagogues have the ability to restore hGl I levels, potentially to the levels found in youth. See for reference the book entitled "Grow Young with hell" by Dr. Ronald Klatz, President of the American Academy of Anti-Aging, published in 1997 by Harper Collins.
In 1981 a study was published by Drs. Isidori, A. Lo Monico and Cappa (Isidor.A., et al Current Medical Research and Opinion 7 #7 (1981 ): 475-481 ) which demonstrated that a specific combination of amino acids, when ingested orally, would cause an increase in growth hormone levels in humans. If offered a more practical and physiological approach to the previously known fact that intravenous administration of amino acids SUBSTITUTE SHEET (RULE 26) strongly stimulates the secretion of human growth hormone by the anterior pituitary gland.
Franco Salomon et al (The New England Journal of Medicine Vol. 321 (26) p.1797-1803) 1989) carried out a 6 month randomized, double blind, placebo controlled trial of recombinant human growth hormone on 24 patients suffering from growth hormone deficiency. They noticed an increase in Insulin-like Growth Factor 1 ("IGF-1"), lean body mass and reduction in fat. Metabolic rate was increased and plasma cholesterol lowered.
J.O.L. Jorgensen et al (Lancet-Jun. 3rd, 1989 p.1221-1225) carried out a 4 month double blind, placebo controlled, crossover study of growth hormone in 22 deficient adults, muscle thickness increased, fat was reduced. Renal plasma flow and glomerular filtration rates were raised from subnormal levels to levels comparable for their age. IGF-1 levels were also normalized.
In 1990 Dr. Daniel Rudman published a research paper (Rudman,D., et al.
"Effects of Human growth Hormone in men over 60 years old", New England Journal of Medicine, 323 (1990): 1-6) which showed that twelve healthy men aged between 61 and 81, following 6 months of human growth hormone therapy, had age reversal effects on lean body mass and adipose tissue mass equivalent in magnitude to changes attributable to 10 to 20 years of aging. In addition, Dr. Rudman et al noted that alterations in body composition, caused by growth hormone deficiency as we age, can be reversed by replacement doses of hormone in other experiments in rodents, children and adults 20 to 50 years old. Dr. Rudman also noted that "these findings suggest that the atrophy of the lean body mass and its (the body's) component organs and the enlargement of the mass of adipose tissue that are characteristic of the elderly results at least in part from diminished secretion of growth hormone. If so, the age-related changes in body composition should be correctable in part by the administration of human growth hormone, now readily available as a bio-synthetic product".
Inventor: Donald Murdoch McLeod, Merritt (CA) SUPPLEMENT FOR RESTORING GROWTH HORMONE LEVELS
FIELD OF THE INVENTION
This invention relates to the field of health supplements, including supplements which elevate release of human growth hormone and prevent oxidative damage, when applied as a cream, when taken orally as a liquid or when taken as a caspule or tablet.
BACKGROUND OF THE INVENTION
Until recently human growth hormone (hereinafter alternatively referred to as hGH) was available only in expensive injectable forms and benefits from the restoration of hGH
levels available only to those with the ability to pay. Most recently natural substances which can trigger the release of human growth hormone from an individual's own anterior pituitary gland have become available. These are generically referred to as secretagogues. Secretagogues have the ability to restore hGl I levels, potentially to the levels found in youth. See for reference the book entitled "Grow Young with hell" by Dr. Ronald Klatz, President of the American Academy of Anti-Aging, published in 1997 by Harper Collins.
In 1981 a study was published by Drs. Isidori, A. Lo Monico and Cappa (Isidor.A., et al Current Medical Research and Opinion 7 #7 (1981 ): 475-481 ) which demonstrated that a specific combination of amino acids, when ingested orally, would cause an increase in growth hormone levels in humans. If offered a more practical and physiological approach to the previously known fact that intravenous administration of amino acids SUBSTITUTE SHEET (RULE 26) strongly stimulates the secretion of human growth hormone by the anterior pituitary gland.
Franco Salomon et al (The New England Journal of Medicine Vol. 321 (26) p.1797-1803) 1989) carried out a 6 month randomized, double blind, placebo controlled trial of recombinant human growth hormone on 24 patients suffering from growth hormone deficiency. They noticed an increase in Insulin-like Growth Factor 1 ("IGF-1"), lean body mass and reduction in fat. Metabolic rate was increased and plasma cholesterol lowered.
J.O.L. Jorgensen et al (Lancet-Jun. 3rd, 1989 p.1221-1225) carried out a 4 month double blind, placebo controlled, crossover study of growth hormone in 22 deficient adults, muscle thickness increased, fat was reduced. Renal plasma flow and glomerular filtration rates were raised from subnormal levels to levels comparable for their age. IGF-1 levels were also normalized.
In 1990 Dr. Daniel Rudman published a research paper (Rudman,D., et al.
"Effects of Human growth Hormone in men over 60 years old", New England Journal of Medicine, 323 (1990): 1-6) which showed that twelve healthy men aged between 61 and 81, following 6 months of human growth hormone therapy, had age reversal effects on lean body mass and adipose tissue mass equivalent in magnitude to changes attributable to 10 to 20 years of aging. In addition, Dr. Rudman et al noted that alterations in body composition, caused by growth hormone deficiency as we age, can be reversed by replacement doses of hormone in other experiments in rodents, children and adults 20 to 50 years old. Dr. Rudman also noted that "these findings suggest that the atrophy of the lean body mass and its (the body's) component organs and the enlargement of the mass of adipose tissue that are characteristic of the elderly results at least in part from diminished secretion of growth hormone. If so, the age-related changes in body composition should be correctable in part by the administration of human growth hormone, now readily available as a bio-synthetic product".
SUBSTITUTE SHEET (RULE 26) The primary purpose of hGH is that of stimulating growth, cell repair and regeneration.
Once the growth period is over, its primary function becomes that of cell regeneration and repair, helping to regenerate skin, bone, heart, lungs, liver and kidneys to their former youthful cell levels. Elevating hGH levels appears to benefit the immune system.
It has also been reported that the risk factors for heart attack and stroke may be potentially diminished. Some patients with emphysema have reported that they are less short of breath. Dr. Rudman's study also demonstrated that bone density in the lumbar spine can improve. It has also been shown that wrinkles of the skin diminish and skin thickness increases. Others have reported improvement in presbyopia (the difficulty in focusing due to hardening of the lenses as we age) with some reporting restoration of hair colour and growth. HGH appears to selectively reduce the fat around the abdomen, hips, waist and thighs while at the same time increasing muscle mass.
In Dr.
Rudman's study, after 6 months of usage, without exercise, the subjects had an average 8% increase in lean muscle mass and a 14.4% loss of fat.
Dr. Cass Terry and Dr. E. Chein reported on the effects of elevating hGH
levels by injection. They showed high frequency-low dose injecti9ons of hGH elevated IGF-levels. Analyzing the clinical effects of elevating hGH in 202 patients (age 39-74) they showed 75% of the individuals described an increase and improvement in sexual potency as well as frequency of sexual relations, while 62% described improvement in 84% of individuals and muscle strength improved in 88%. A 71 % increase in healing capacity was noted.
It appears that hGH not only has the ability to restore sexual potency and sexuality in older men, but acts as a mood elevator, restoring a youthful sense of wellness as well as improving sleep. With its potential for affecting cell regeneration and repair, healing of injuries should improve.
HGH, alternatively referred to herein by its medical name Somatotropin, is produced in the anterior pituitary gland situated just below the hypothalamus which is itself situated just below the cerebral cortex of the brain. HGH is one of the several hormones secreted by the anterior pituitary gland and, as noted above, influences the growth, SUBSTITUTE SHEET (RULE 26) regeneration and repair of cells, bones, muscles and organs throughout the body throughout life. Production peaks at adolescence when accelerated growth is occurring and if growing children are deficient in human growth hormone, they remain as pituitary dwarfs. If they have too much they exhibit gigantism (acromegaly).
As is the case with many of our other hormones or their pre-cursors, such as testosterone, oestrogen, progesterone, DHEA and melatonin, hGH levels decline with age. Therapeutically, many of these hormones can be replaced to offset some of the effects of aging such as menopausal symptoms in women or andropausal symptoms in men.
The human body, like every other living entity, works on a daily, or circadian, as well as monthly and annual rhythms. Daily growth hormone secretion diminishes with age with roughly half the levels at age forty that we had when we were 20, and about 1/3rd of those youthful levels at age 60. In some 60-year-olds the levels are as low as 25% of the hGH levels in a 20-year-old. Symptoms of aging include decrease in immune function, loss of muscle, increase offat, decreased physical mobility, decreased energy levels and as a result, diminished socialization, diminished healing ability and an increased risk of cardiovascular disease and decreased life expectancy.
Low hGH levels are associated with the aging process and early onset of disease. For example, Rosen and Bengtsson noted an increased death rate from cardiovascular disease in hGH deficient patients (Rose,T., Bengtsson, B.A., Lancet 336 (1990): 285-2880). Furthermore, the mechanism of hGH release has been elucidated and is considered to be under the control of Growth Hormone Releasing Hormone (GHRH) and Somatostatin. Somatostatin prevents further release of hGH form the pituitary gland. ~It has been postulated that one of the key factors in aging is an imbalance in the levels of GHRH and Somatostatin in the combined GHRH/Somatostatin secretion, with an increased action or effectiveness of Somatostatin over GHRH. This leads to an effective reduction in release ofthe stored hGH form the anterior pituitary gland. Isodori et al have shown the selected amino acids arginine and lysine increase the release of the body's own stored, natural hGH, when taken orally. Matteini showed even low SUBSTITUTE SHEET (RULE 26) doses of arginine in the region of 200mg can elevated hGH release.
(Matteini.M., et al.
Bollettino-Societa Iraliana Biolgoia Sperimentale. 56(21 ) 2254-60, Nov.151980). It has been suggested that one of the mechanisms of action is the inhibitory effect of arginine, and possibly other amino acids, on the secretion and action of Somatostatin (Alba-Roth, J., Muller, O.A., Schopohl, J. et al. Journal of Clinical Endocrinology and Metabolism 67, #6 (1998): 1186-1189).
HGH, once released by the pituitary gland, travels in the circulation and is taken up by the cells and principally by the liver there is production of IGF-1. IGF-1 is then released into the circulation where it attaches to cells in the body and like insulin, triggers the cell to produce certain responses which, with IGF-1, are those of growth, regeneration and repair. Levels of IGF-1 are monitored by the hypothalamus situated just above the pituitary gland. When maximal hGH levels are attained for any individual, these levels trigger the release of Somatostatin. This feedback loop prevents excessive levels of hGH in the body. This feedback loop is extremely efficient at monitoring and maintaining the hGH (and therefore IGF-1) at the optimal level for the individual.
In the prior art, the use of amino acids has essentially been limited to applications where the amino acids have been used as feeding preparations. The amino acids are the final form in which protein is digested from the gastrointestinal tract in mammals.
They are essentially digested protein broken into its smallest molecular components amino acids. Given in natural physiological blends, such as those that are found occurring naturally in natural proteins such as meat, dairy products, eggs, fish and plants, they can provide the body with the protein nutrients required without the need to pass through the gastrointestinal tract for digestion, ie break down to amino acids if they are given intravenously to sustain health.
It is thus one object of the present invention to provide a health supplement for elevating hGH release, in particular an amino acid stack, for a synergistic, well tolerated supplemental having the result of increasing or elevating hGH release in those individuals where hGH release rates have slowed as a function of increasing age.
Once the growth period is over, its primary function becomes that of cell regeneration and repair, helping to regenerate skin, bone, heart, lungs, liver and kidneys to their former youthful cell levels. Elevating hGH levels appears to benefit the immune system.
It has also been reported that the risk factors for heart attack and stroke may be potentially diminished. Some patients with emphysema have reported that they are less short of breath. Dr. Rudman's study also demonstrated that bone density in the lumbar spine can improve. It has also been shown that wrinkles of the skin diminish and skin thickness increases. Others have reported improvement in presbyopia (the difficulty in focusing due to hardening of the lenses as we age) with some reporting restoration of hair colour and growth. HGH appears to selectively reduce the fat around the abdomen, hips, waist and thighs while at the same time increasing muscle mass.
In Dr.
Rudman's study, after 6 months of usage, without exercise, the subjects had an average 8% increase in lean muscle mass and a 14.4% loss of fat.
Dr. Cass Terry and Dr. E. Chein reported on the effects of elevating hGH
levels by injection. They showed high frequency-low dose injecti9ons of hGH elevated IGF-levels. Analyzing the clinical effects of elevating hGH in 202 patients (age 39-74) they showed 75% of the individuals described an increase and improvement in sexual potency as well as frequency of sexual relations, while 62% described improvement in 84% of individuals and muscle strength improved in 88%. A 71 % increase in healing capacity was noted.
It appears that hGH not only has the ability to restore sexual potency and sexuality in older men, but acts as a mood elevator, restoring a youthful sense of wellness as well as improving sleep. With its potential for affecting cell regeneration and repair, healing of injuries should improve.
HGH, alternatively referred to herein by its medical name Somatotropin, is produced in the anterior pituitary gland situated just below the hypothalamus which is itself situated just below the cerebral cortex of the brain. HGH is one of the several hormones secreted by the anterior pituitary gland and, as noted above, influences the growth, SUBSTITUTE SHEET (RULE 26) regeneration and repair of cells, bones, muscles and organs throughout the body throughout life. Production peaks at adolescence when accelerated growth is occurring and if growing children are deficient in human growth hormone, they remain as pituitary dwarfs. If they have too much they exhibit gigantism (acromegaly).
As is the case with many of our other hormones or their pre-cursors, such as testosterone, oestrogen, progesterone, DHEA and melatonin, hGH levels decline with age. Therapeutically, many of these hormones can be replaced to offset some of the effects of aging such as menopausal symptoms in women or andropausal symptoms in men.
The human body, like every other living entity, works on a daily, or circadian, as well as monthly and annual rhythms. Daily growth hormone secretion diminishes with age with roughly half the levels at age forty that we had when we were 20, and about 1/3rd of those youthful levels at age 60. In some 60-year-olds the levels are as low as 25% of the hGH levels in a 20-year-old. Symptoms of aging include decrease in immune function, loss of muscle, increase offat, decreased physical mobility, decreased energy levels and as a result, diminished socialization, diminished healing ability and an increased risk of cardiovascular disease and decreased life expectancy.
Low hGH levels are associated with the aging process and early onset of disease. For example, Rosen and Bengtsson noted an increased death rate from cardiovascular disease in hGH deficient patients (Rose,T., Bengtsson, B.A., Lancet 336 (1990): 285-2880). Furthermore, the mechanism of hGH release has been elucidated and is considered to be under the control of Growth Hormone Releasing Hormone (GHRH) and Somatostatin. Somatostatin prevents further release of hGH form the pituitary gland. ~It has been postulated that one of the key factors in aging is an imbalance in the levels of GHRH and Somatostatin in the combined GHRH/Somatostatin secretion, with an increased action or effectiveness of Somatostatin over GHRH. This leads to an effective reduction in release ofthe stored hGH form the anterior pituitary gland. Isodori et al have shown the selected amino acids arginine and lysine increase the release of the body's own stored, natural hGH, when taken orally. Matteini showed even low SUBSTITUTE SHEET (RULE 26) doses of arginine in the region of 200mg can elevated hGH release.
(Matteini.M., et al.
Bollettino-Societa Iraliana Biolgoia Sperimentale. 56(21 ) 2254-60, Nov.151980). It has been suggested that one of the mechanisms of action is the inhibitory effect of arginine, and possibly other amino acids, on the secretion and action of Somatostatin (Alba-Roth, J., Muller, O.A., Schopohl, J. et al. Journal of Clinical Endocrinology and Metabolism 67, #6 (1998): 1186-1189).
HGH, once released by the pituitary gland, travels in the circulation and is taken up by the cells and principally by the liver there is production of IGF-1. IGF-1 is then released into the circulation where it attaches to cells in the body and like insulin, triggers the cell to produce certain responses which, with IGF-1, are those of growth, regeneration and repair. Levels of IGF-1 are monitored by the hypothalamus situated just above the pituitary gland. When maximal hGH levels are attained for any individual, these levels trigger the release of Somatostatin. This feedback loop prevents excessive levels of hGH in the body. This feedback loop is extremely efficient at monitoring and maintaining the hGH (and therefore IGF-1) at the optimal level for the individual.
In the prior art, the use of amino acids has essentially been limited to applications where the amino acids have been used as feeding preparations. The amino acids are the final form in which protein is digested from the gastrointestinal tract in mammals.
They are essentially digested protein broken into its smallest molecular components amino acids. Given in natural physiological blends, such as those that are found occurring naturally in natural proteins such as meat, dairy products, eggs, fish and plants, they can provide the body with the protein nutrients required without the need to pass through the gastrointestinal tract for digestion, ie break down to amino acids if they are given intravenously to sustain health.
It is thus one object of the present invention to provide a health supplement for elevating hGH release, in particular an amino acid stack, for a synergistic, well tolerated supplemental having the result of increasing or elevating hGH release in those individuals where hGH release rates have slowed as a function of increasing age.
SUBSTITUTE SHEET (RULE 26) SUMMARY OF THE INVENTION
The present invention is a health supplement. It is an amino acid stack secretagogue, which, taken orally, or is applied topically, stimulates the pituitary gland to produce hGH
/ Somatotropin. The amino acids may be in the "L" or "D" or "D/L" isomer or may be combinations thereof. One object of the present invention is to elevate hGH/Somatotropin release. This has the further result of increasing IGF-1 levels.
Further objects of the present invention may also result, namely, inhibiting insulin depression; inhibiting hyper-glycaemia (low blood glucose) and increasing insulin effectiveness: enhancing fat conversion, assisting in lowering cholesterol, and normalizing lipid balance and providing some degree of antioxidant protection from free radical production.
In one embodiment of the invention a supplement for humans or other mammals for restoring growth hormone levels is provided. The supplement comprises unmodified rapidly absorbed free-form amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which, when provided to a user, stimulate release of growth hormones in the user, said amino acids comprising:
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v ) glycine.
In one aspect of the invention, the supplement is a nutritional supplement.
The present invention is a health supplement. It is an amino acid stack secretagogue, which, taken orally, or is applied topically, stimulates the pituitary gland to produce hGH
/ Somatotropin. The amino acids may be in the "L" or "D" or "D/L" isomer or may be combinations thereof. One object of the present invention is to elevate hGH/Somatotropin release. This has the further result of increasing IGF-1 levels.
Further objects of the present invention may also result, namely, inhibiting insulin depression; inhibiting hyper-glycaemia (low blood glucose) and increasing insulin effectiveness: enhancing fat conversion, assisting in lowering cholesterol, and normalizing lipid balance and providing some degree of antioxidant protection from free radical production.
In one embodiment of the invention a supplement for humans or other mammals for restoring growth hormone levels is provided. The supplement comprises unmodified rapidly absorbed free-form amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which, when provided to a user, stimulate release of growth hormones in the user, said amino acids comprising:
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v ) glycine.
In one aspect of the invention, the supplement is a nutritional supplement.
SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, a supplement for humans or other mammals for restoring growth hormone levels is provided. The supplement comprises unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which, when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids consist of the amino acids and derivatives thereof methionine, carnitine, N-acetyl-cysteine, lysine, glutamine, ornithine, glycine and arginine.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, a supplement for humans or other mammals for restoring growth hormone levels is provided. The supplement comprises unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which, when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids consist of the amino acids and derivatives thereof methionine, carnitine, N-acetyl-cysteine, lysine, glutamine, ornithine, glycine and arginine.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, a supplement for humans or other mammals for restoring growth hormone levels is provided. The supplement comprises unmodified rapidly absorbed free-form amino acids, in an amino acid stack and additives, and which, when provided to a user, stimulates release of growth hormone in the user, said amino acids consisting ofthe amino acids and derivatives thereof methionine, carnitine, N-acetyl-cysteine, lysine, glutamine, ornithine, glycine and arginine.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, a supplement for restoring growth hormone levels, the supplement for humans or other mammals in a daily dosage is provided. The supplement and comprises unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids or derivatives thereof in the daily dosage comprises:
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg (e) Glycine in the mass range 25mg and 500mg _g_ SUBSTITUTE SHEET (RULE 26) (f) Methionine in the mass range Omg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1 OOOmg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, the amino acids or derivatives thereof in the daily dosage comprise:
(a) 150mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
In one aspect of the invention, the supplement is a nutritional supplement.
_g_ SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, a supplement for restoring growth hormone levels is provided. The supplement is for humans or other mammals in a daily dosage and comprises unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack and additives , and which when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids or derivatives thereof in the daily dosage comprising:
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg . (e) Glycine in the mass range 25mg and 500mg (f) Methionine in the mass range Omg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1 OOOmg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, the amino acids or derivatives thereof in the daily dosage comprise:
(a) 1500mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, a supplement for humans or other mammals for restoring growth hormone levels is provided. The supplement comprises unmodified rapidly absorbed free-form amino acids, in an amino acid stack and additives, and which, when provided to a user, stimulate release of growth hormones in the user, said amino acids comprising:
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v) glycine.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
SUBSTITUTE SHEET (RULE 26) DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
As noted above, elevating hGH levels elevated IGF-A levels. This can be achieved by secretagogue hGH releasers without the need for injection therapy or oral-hGH
forms, or gene manipulation. Secretagogues maintain the body's own natural feedback loop, thus not only releasing hGH naturally but safely. Natural secretagogues may have the ability to more closely mimic the body's youthful hGH secretion patterns than any other hGH therapies currently available. Use of a secretagogue such as the supplement of the present invention has the potential for restoring the body's hGH and IGF-1 levels without interfering with the body's own feedback loop. The supplement of the present invention contains amino acids, formulated as a dietary supplement.
Some amino acids can be made in the body from basic building blocks, but others (9 out of the 20 needed for protein building) are called essential amino acids as the body is unable to manufacture them and they have to be supplied in the food that we eat.
Arginine is an amino acid important in creating synthesis. Claims for Arginine include an increase in fat-burning and muscle-building, as well as strengthening the thymus gland by increasing its weight and activity and thereby boosting immunity.
There are also claims that Arginine alone will promote healing of burns and wounds, as well as enhance male fertility.
Arginine along with Lysine has been demonstrated to cause hGH release when combined in specific proportions. Essentially, amino acids contained in the supplement of the present invention are arginine, lysine, carnitine, N-acetyl-cysteine, ornithine, methionine, glutamine and glycine. Lysine boosts the effectiveness of Arginine and is also said to affect growth, as well as having immune-boosting properties of its own and may inhibit collagenase to prevent cell matrix breakdown and metastases.
Ornithine can be synthesized in the body and is now also known to help stimulate hGH
release.
Glutamine can also be synthesized in the body but may not always be made by the body in sufficient quantities in times of stress. Without sufficiently available levels, the gastrointestinal tract does not function as well, and nutrients are less well absorbed.
SUBSTITUTE SHEET (RULE 26) Other amino acids in the supplement of the present invention contribute to the effects of the supplement and the synergy of the amino acids listed above. This type of combination of amino acids is known as an amino acid stack.
The supplement of the present invention works as a dietary supplement by assisting the body's own ability to secrete hGH or Growth Hormone naturally in a manner which is safe and effective, as well as being affordable. When starting the supplement of the present invention it should be taken for a minimum of 3 months, preferably along with a dietary and exercise regime in order to ensure maximal benefits. Continued usage is suggested for maximum benefit but it is also recommended that it can be taken on a 5 days per week cycle followed by two days off, or six days per week with one day off, based on our current state of knowledge. The supplement of the present invention may be formulated in a capsule form or as a tablet, or as a liquid for ease of ingestion. It should be taken on an empty stomach. This ensures that it is rapidly absorbed into the bloodstream as shown by experiment on human subjects as done for this invention.
The supplement of the invention also works as a topically applied supplement by assisting the body's own ability to secrete hGH. Topical applications may be as a cream or ointment, for example, but not to be limiting. The formulation may include compounds to promote the uptake of the supplement through the skin.
What is not taught nor suggested in the prior art, and which the supplement of the present invention provides is the use, in the below disclosed combination and proportions, of amino acids including lysine, glutamine and ornithine, alternatively to also include arginine, to inhibit insulin depression, often seen when hGH
levels are elevated. The supplement of the present invention in the specified quantity of glutamine inhibits hyperglycaemia, while ensuring a natural anabolic muscle building effect by increasing insulin effectiveness. In the supplement of the present invention orinithine is combined with glutamine to enhance fat conversion and assist in lowering cholesterol, while nomalizing lipid balance. In the supplement of the present invention, in the specified combination and quantities, amino acids are stacked amino acid secretagogues resulting in balancing glucose, insulin and blood lipids. The supplement SUBSTITUTE SHEET (RULE 26) of the present invention includes the amino acids carnitine, methionine and N-acetyl-cysteine so as to provide essential nutrients, antioxidants and energy for muscle regeneration and repair. This is of particular importance when a secretagogue is used before exercise. Methionine helps with mobilize fat storage and also acts as a powerful antioxidant, crossing the blood brain barrier to remove heavy toxic metals. L-carnitine not only works as a secretogoue, but also helps transport long chain fatty acids to muscle tissue where it can be metabolized to produce more energy from the mitochondria.
The combination of types of amino acids, mass ranges and specific formulations have been selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release. Improper combinations of the amino acids or insufficient quantities of amino acid salts will be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, arginine, lysine, glutamine, ornithine and glycine, synergistically stimulate the release of human growth hormone. The combination was also chosen to inhibit chemical combination or reaction between the amino acids. Such will not occur because of the crystalline free-form amino acid salts that have been chosen.
A further novel aspect of the supplement of the present invention is the addition of the carnitine, which functions via several mechanisms to protect cells by assisting in the transport of fats through the cell membrane and into the mitochondria to produce cellular energy via ATP. N-acetyl-cysteine, the acetylated form of L-cysteine is an efficiently orally absorbed antioxidant and boosts glutathione levels in the cells.
Methionine is an important antioxidant as well. All of these amino acids have a synergistic effect in combination with the human growth hormone that is released in helping to build and improve muscle mass and strength and preventing oxidative damage as hGH stimulates protein synthesis and energy production.
With regard to the individual amino acids in particular, ornithine is synergistic with arginine in elevating hGH levels as is lysine synergistic with arginine in elevating hGH
levels. Glutamine will elevate hGH levels independently and there is some evidence SUBSTITUTE SHEET (RULE 26) of a synergistic effect with the 3 others mentioned above with glycine also producing independent induction of hGH secretion and synergy with the others. The amino acids, carnitine, N-acetyl-cysteine and methionine all have been shown to promote muscle tissue repair and growth and prevent oxidative damage particularly in conjunction with human growth hormone, as well as increased muscle energy and improvement in skin and wound healing. This in turn would of course help with exercise as vigorous exercise induces a mild level of muscle damage resulting in the aching effect that people notice when they have not been exercising for a while and start to exercise.
The products comprise a combination of amino acids in a free-form crystalline state.
This may help avoiding an interaction or chain reaction between the amino acids. Such an interaction or chain reaction could result in deterioration and breakdown in the integrity of the product. The free-form crystalline state also reduces the possibility of interaction with the vegetarian gel cap in which the product may be packaged.
In one preferred embodiment, the supplement of the present invention formulation for a one day does, in 6-5 size 00 capsules, includes the following amino acids and derivatives thereof in the specified approximate mass ranges.
Lysine 500mg -1500mg Ornithine 100mg -1500mg Glutamine 100mg -1000mg Glycine 10mg - 500mg Carnitine 50mg -1000mg Methionine Omg - 500mg N-Acetyl-Cysteine100mg -1000mg Another preferred embodiment may further include:
Arginine 500mg -1500mg SUBSTITUTE SHEET (RULE 26) In particular, in one preferred embodiment, the supplement of the present invention my have the following specific composition:
L-Lysine 1500mg L-Ornithine 500mg Glycine 50mg L-Glutamine 250mg L-Carnitine 500mg L-Methionine 50mg N-Acetyl-Cysteine250mg In another specific formulation, the supplement of the present invention may further include:
L-Arginine 1500mg In which case, the amount of L-Ornithine may be reduced to 100mg and the amount of L-Lysine reduced to 1200mg.
As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations and modifications are possible in the practice of this invention without departing from the spirit or scope thereof For example, formulations for topical application may include sprays. Similarly, liquid formulations for ingestion may be suspensions or may be solutions. Additives in the form of non-amino acid supplements may be additionally added, for example, but not to be limited to, vitamins and minerals.
SUBSTITUTE SHEET (RULE 26)
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, a supplement for restoring growth hormone levels, the supplement for humans or other mammals in a daily dosage is provided. The supplement and comprises unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids or derivatives thereof in the daily dosage comprises:
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg (e) Glycine in the mass range 25mg and 500mg _g_ SUBSTITUTE SHEET (RULE 26) (f) Methionine in the mass range Omg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1 OOOmg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, the amino acids or derivatives thereof in the daily dosage comprise:
(a) 150mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
In one aspect of the invention, the supplement is a nutritional supplement.
_g_ SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, a supplement for restoring growth hormone levels is provided. The supplement is for humans or other mammals in a daily dosage and comprises unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack and additives , and which when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids or derivatives thereof in the daily dosage comprising:
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg . (e) Glycine in the mass range 25mg and 500mg (f) Methionine in the mass range Omg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1 OOOmg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
In another aspect of the invention, the amino acids or derivatives thereof in the daily dosage comprise:
(a) 1500mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
SUBSTITUTE SHEET (RULE 26) In another aspect of the invention, a supplement for humans or other mammals for restoring growth hormone levels is provided. The supplement comprises unmodified rapidly absorbed free-form amino acids, in an amino acid stack and additives, and which, when provided to a user, stimulate release of growth hormones in the user, said amino acids comprising:
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v) glycine.
In one aspect of the invention, the supplement is a nutritional supplement.
In another aspect of the invention, the supplement is provided in the form of one of a tablet, a capsule or a liquid.
In another aspect of the invention, the supplement is provided as a suitably selected formulation for topical application.
In another aspect of the invention, the formulation is either a cream or an ointment.
In another aspect of the invention, the formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
SUBSTITUTE SHEET (RULE 26) DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
As noted above, elevating hGH levels elevated IGF-A levels. This can be achieved by secretagogue hGH releasers without the need for injection therapy or oral-hGH
forms, or gene manipulation. Secretagogues maintain the body's own natural feedback loop, thus not only releasing hGH naturally but safely. Natural secretagogues may have the ability to more closely mimic the body's youthful hGH secretion patterns than any other hGH therapies currently available. Use of a secretagogue such as the supplement of the present invention has the potential for restoring the body's hGH and IGF-1 levels without interfering with the body's own feedback loop. The supplement of the present invention contains amino acids, formulated as a dietary supplement.
Some amino acids can be made in the body from basic building blocks, but others (9 out of the 20 needed for protein building) are called essential amino acids as the body is unable to manufacture them and they have to be supplied in the food that we eat.
Arginine is an amino acid important in creating synthesis. Claims for Arginine include an increase in fat-burning and muscle-building, as well as strengthening the thymus gland by increasing its weight and activity and thereby boosting immunity.
There are also claims that Arginine alone will promote healing of burns and wounds, as well as enhance male fertility.
Arginine along with Lysine has been demonstrated to cause hGH release when combined in specific proportions. Essentially, amino acids contained in the supplement of the present invention are arginine, lysine, carnitine, N-acetyl-cysteine, ornithine, methionine, glutamine and glycine. Lysine boosts the effectiveness of Arginine and is also said to affect growth, as well as having immune-boosting properties of its own and may inhibit collagenase to prevent cell matrix breakdown and metastases.
Ornithine can be synthesized in the body and is now also known to help stimulate hGH
release.
Glutamine can also be synthesized in the body but may not always be made by the body in sufficient quantities in times of stress. Without sufficiently available levels, the gastrointestinal tract does not function as well, and nutrients are less well absorbed.
SUBSTITUTE SHEET (RULE 26) Other amino acids in the supplement of the present invention contribute to the effects of the supplement and the synergy of the amino acids listed above. This type of combination of amino acids is known as an amino acid stack.
The supplement of the present invention works as a dietary supplement by assisting the body's own ability to secrete hGH or Growth Hormone naturally in a manner which is safe and effective, as well as being affordable. When starting the supplement of the present invention it should be taken for a minimum of 3 months, preferably along with a dietary and exercise regime in order to ensure maximal benefits. Continued usage is suggested for maximum benefit but it is also recommended that it can be taken on a 5 days per week cycle followed by two days off, or six days per week with one day off, based on our current state of knowledge. The supplement of the present invention may be formulated in a capsule form or as a tablet, or as a liquid for ease of ingestion. It should be taken on an empty stomach. This ensures that it is rapidly absorbed into the bloodstream as shown by experiment on human subjects as done for this invention.
The supplement of the invention also works as a topically applied supplement by assisting the body's own ability to secrete hGH. Topical applications may be as a cream or ointment, for example, but not to be limiting. The formulation may include compounds to promote the uptake of the supplement through the skin.
What is not taught nor suggested in the prior art, and which the supplement of the present invention provides is the use, in the below disclosed combination and proportions, of amino acids including lysine, glutamine and ornithine, alternatively to also include arginine, to inhibit insulin depression, often seen when hGH
levels are elevated. The supplement of the present invention in the specified quantity of glutamine inhibits hyperglycaemia, while ensuring a natural anabolic muscle building effect by increasing insulin effectiveness. In the supplement of the present invention orinithine is combined with glutamine to enhance fat conversion and assist in lowering cholesterol, while nomalizing lipid balance. In the supplement of the present invention, in the specified combination and quantities, amino acids are stacked amino acid secretagogues resulting in balancing glucose, insulin and blood lipids. The supplement SUBSTITUTE SHEET (RULE 26) of the present invention includes the amino acids carnitine, methionine and N-acetyl-cysteine so as to provide essential nutrients, antioxidants and energy for muscle regeneration and repair. This is of particular importance when a secretagogue is used before exercise. Methionine helps with mobilize fat storage and also acts as a powerful antioxidant, crossing the blood brain barrier to remove heavy toxic metals. L-carnitine not only works as a secretogoue, but also helps transport long chain fatty acids to muscle tissue where it can be metabolized to produce more energy from the mitochondria.
The combination of types of amino acids, mass ranges and specific formulations have been selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release. Improper combinations of the amino acids or insufficient quantities of amino acid salts will be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, arginine, lysine, glutamine, ornithine and glycine, synergistically stimulate the release of human growth hormone. The combination was also chosen to inhibit chemical combination or reaction between the amino acids. Such will not occur because of the crystalline free-form amino acid salts that have been chosen.
A further novel aspect of the supplement of the present invention is the addition of the carnitine, which functions via several mechanisms to protect cells by assisting in the transport of fats through the cell membrane and into the mitochondria to produce cellular energy via ATP. N-acetyl-cysteine, the acetylated form of L-cysteine is an efficiently orally absorbed antioxidant and boosts glutathione levels in the cells.
Methionine is an important antioxidant as well. All of these amino acids have a synergistic effect in combination with the human growth hormone that is released in helping to build and improve muscle mass and strength and preventing oxidative damage as hGH stimulates protein synthesis and energy production.
With regard to the individual amino acids in particular, ornithine is synergistic with arginine in elevating hGH levels as is lysine synergistic with arginine in elevating hGH
levels. Glutamine will elevate hGH levels independently and there is some evidence SUBSTITUTE SHEET (RULE 26) of a synergistic effect with the 3 others mentioned above with glycine also producing independent induction of hGH secretion and synergy with the others. The amino acids, carnitine, N-acetyl-cysteine and methionine all have been shown to promote muscle tissue repair and growth and prevent oxidative damage particularly in conjunction with human growth hormone, as well as increased muscle energy and improvement in skin and wound healing. This in turn would of course help with exercise as vigorous exercise induces a mild level of muscle damage resulting in the aching effect that people notice when they have not been exercising for a while and start to exercise.
The products comprise a combination of amino acids in a free-form crystalline state.
This may help avoiding an interaction or chain reaction between the amino acids. Such an interaction or chain reaction could result in deterioration and breakdown in the integrity of the product. The free-form crystalline state also reduces the possibility of interaction with the vegetarian gel cap in which the product may be packaged.
In one preferred embodiment, the supplement of the present invention formulation for a one day does, in 6-5 size 00 capsules, includes the following amino acids and derivatives thereof in the specified approximate mass ranges.
Lysine 500mg -1500mg Ornithine 100mg -1500mg Glutamine 100mg -1000mg Glycine 10mg - 500mg Carnitine 50mg -1000mg Methionine Omg - 500mg N-Acetyl-Cysteine100mg -1000mg Another preferred embodiment may further include:
Arginine 500mg -1500mg SUBSTITUTE SHEET (RULE 26) In particular, in one preferred embodiment, the supplement of the present invention my have the following specific composition:
L-Lysine 1500mg L-Ornithine 500mg Glycine 50mg L-Glutamine 250mg L-Carnitine 500mg L-Methionine 50mg N-Acetyl-Cysteine250mg In another specific formulation, the supplement of the present invention may further include:
L-Arginine 1500mg In which case, the amount of L-Ornithine may be reduced to 100mg and the amount of L-Lysine reduced to 1200mg.
As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations and modifications are possible in the practice of this invention without departing from the spirit or scope thereof For example, formulations for topical application may include sprays. Similarly, liquid formulations for ingestion may be suspensions or may be solutions. Additives in the form of non-amino acid supplements may be additionally added, for example, but not to be limited to, vitamins and minerals.
SUBSTITUTE SHEET (RULE 26)
Claims (48)
1. A supplement for humans or other mammals for restoring growth hormone levels comprising unmodified rapidly absorbed free-form amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which, when provided to a user, stimulate release of growth hormones in the user, said amino acids comprising:
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v) glycine.
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v) glycine.
2. The supplement of claim 1 wherein said supplement is a nutritional supplement.
3. The supplement of claim 2 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
4. The supplement of claim 1 wherein said supplement is provided as a suitably selected formulation for topical application.
5. The supplement of claim 4 wherein said formulation is either a cream or an ointment.
6. The supplement of claim 5 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
7. A supplement for humans or other mammals for restoring growth hormone levels comprising unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which, when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids comprise the amino acids and derivatives thereof methionine, carnitine, N-acetyl-cysteine, lysine, glutamine, ornithine, glycine and arginine.
8. The supplement of claim 7 wherein said supplement is a nutritional supplement.
9. The supplement of claim 8 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
10. The supplement of claim 7 wherein said supplement is provided as a suitably selected formulation for topical application.
11. The supplement of claim 10 wherein said formulation is either a cream or an ointment.
12. The supplement of claim 11 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
13. A supplement for humans or other mammals for restoring growth hormone levels comprising of unmodified rapidly absorbed free-form amino acids, in an amino acid stack and additives, and which, when provided to a user, stimulates release of growth hormone in the user, said amino acids comprising of the amino acids and derivatives thereof methionine, carnitine, N-acetyl-cysteine, lysine, glutamine, ornithine, glycine and arginine.
14. The supplement of claim 13 wherein said supplement is a nutritional supplement.
15. The supplement of claim 14 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
16. The supplement of claim 13 wherein said supplement is provided as a suitably selected formulation for topical application.
17. The supplement of claim 16 wherein said formulation is either a cream or an ointment.
18. The supplement of claim 17 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
19. A supplement for restoring growth hormone levels, the supplement for humans or other mammals in a daily dosage and comprising unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid supplementation, and which when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids or derivatives thereof in the daily dosage comprising:
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg (e) Glycine in the mass range 25mg and 500mg (f) Methionine in the mass range Omg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1000mg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg (e) Glycine in the mass range 25mg and 500mg (f) Methionine in the mass range Omg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1000mg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
20. The supplement of claim 19 wherein said supplement is a nutritional supplement.
21. The supplement of claim 20 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
22. The supplement of claim 19 wherein said supplement is provided as a suitably selected formulation for topical application.
23. The supplement of claim 22 wherein said formulation is either a cream or an ointment.
24. The supplement of claim 23 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
25. The supplement of claim 19, wherein said amino acids or derivatives thereof in the daily dosage comprising:
(a) 1500mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
(a) 1500mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
26. The supplement of claim 25 wherein said supplement is a nutritional supplement.
27. The supplement of claim 26 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
28. The supplement of claim 25 wherein said supplement is provided as a suitably selected formulation for topical application.
29. The supplement of claim 28 wherein said formulation is either a cream or an ointment.
30. The supplement of claim 29 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
31. A supplement for restoring growth hormone levels, the supplement for humans or other mammals in a daily dosage and comprising unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack and additives , and which when provided to a user, stimulates release of growth hormone in the user, wherein said amino acids or derivatives thereof in the daily dosage comprising:
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg (e) Glycine in the mass range 25mg and 500mg (f) Methionine in the mass range 0mg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1000mg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
(a) Lysine in the mass range 500mg and 1500mg (b) Arginine in the mass range 500mg and 1500mg (c) Ornithine in the mass range 100mg and 500mg (d) Glutamine, or L-Pyroglutamic Acid in the mass range 100mg and 500mg (e) Glycine in the mass range 25mg and 500mg (f) Methionine in the mass range 0mg and 500mg (g) Carnitine or Acetyl-Carnitine in the mass range 50mg and 1000mg (h) N-Acetyl-Cysteine in the mass range 50mg and 1000mg.
32. The supplement of claim 31 wherein said supplement is a nutritional supplement.
33. The supplement of claim 32 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
34. The supplement of claim 31 wherein said supplement is provided as a suitably selected formulation for topical application.
35. The supplement of claim 34 wherein said formulation is either a cream or an ointment.
36. The supplement of claim 36 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
37. The supplement of claim 31, wherein said amino acids or derivatives thereof in the daily dosage comprising:
(a) 1500mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
(a) 1500mg of L-Lysine (b) 1500mg of L-Arginine (c) 250mg of L-Ornithine (d) 50 mg of Glycine (e) 250mg of L-Glutamine (f) 50 mg of DL- Methionine or L-Methionine (g) 500mg of L-Carnitine or Acetyl-L-Carnitine (h) 250mg of N-Acetyl-Cysteine.
38. The supplement of claim 37 wherein said supplement is a nutritional supplement.
39. The supplement of claim 38 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
40. The supplement of claim 37 wherein said supplement is provided as a suitably selected formulation for topical application.
41. The supplement of claim 40 wherein said formulation is either a cream or an ointment.
42. The supplement of claim 41 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
43. A supplement for humans or other mammals for restoring growth hormone levels comprising unmodified rapidly absorbed free-form amino acids, in an amino acid stack and additives, and which, when provided to a user, stimulate release of growth hormones in the user, said amino acids comprising:
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v ) glycine.
(a) amino acids and derivatives thereof chosen from the group:
(i) carnitine (ii) methionine (iii) N-acetyl-cysteine (b) free form amino acids chose from the group:
(i) lysine (ii) glutamine (iii) ornithine (iv) arginine (v ) glycine.
44. The supplement of claim 43 wherein said supplement is a nutritional supplement.
45. The supplement of claim 44 wherein said supplement is provided in the form of one of a tablet, a capsule or a liquid.
46. The supplement of claim 43 wherein said supplement is provided as a suitably selected formulation for topical application.
47. The supplement of claim 46 wherein said formulation is either a cream or an ointment.
48. The supplement of claim 47 wherein said formulation further comprises suitably selected compounds to encourage uptake of said supplement through the skin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48249503P | 2003-06-26 | 2003-06-26 | |
| US60/482,495 | 2003-06-26 | ||
| PCT/CA2004/000953 WO2004112511A2 (en) | 2003-06-26 | 2004-06-25 | Supplement for restoring growth hormone levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2529317A1 true CA2529317A1 (en) | 2004-12-29 |
Family
ID=33539349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002529317A Abandoned CA2529317A1 (en) | 2003-06-26 | 2004-06-25 | Supplement for restoring growth hormone levels |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA2529317A1 (en) |
| WO (1) | WO2004112511A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0401422A2 (en) * | 2004-07-15 | 2006-04-28 | G Laszlo Meszaros | Use of l-arginine as vasoaktive ingredient absorbing through skin for external application |
| EP2742938B1 (en) * | 2011-08-08 | 2018-05-09 | Ajinomoto Co., Inc. | Amino-acid-containing composition for enhancing recovery from muscle fatigue |
| US10300101B2 (en) | 2012-09-19 | 2019-05-28 | Quality IP Holdings, LLC | Methods and compositions for enhancing or maintaining fertility |
| US8747921B2 (en) * | 2012-09-19 | 2014-06-10 | Quality Ip Holdings, Inc. | Methods for improving health in humans |
| US8747922B2 (en) | 2012-09-19 | 2014-06-10 | Quality Ip Holdings, Inc. | Methods and compositions for increasing sex steroids and growth hormones |
| US9198889B2 (en) | 2012-09-19 | 2015-12-01 | Quality IP Holdings, LLC | Methods for treating post-traumatic stress disorder |
| US8715752B2 (en) | 2012-09-20 | 2014-05-06 | Quality Ip Holdings, Inc. | Compositions for increasing human growth hormone levels |
| US8734864B2 (en) * | 2012-09-20 | 2014-05-27 | Quality Ip Holdings, Inc. | Methods for increasing human growth hormone levels |
| US9066953B2 (en) | 2012-09-20 | 2015-06-30 | Quality IP Holdings, LLC | Methods for increasing endurance and fat metabolism in humans |
| US10292957B2 (en) | 2012-09-20 | 2019-05-21 | Quality IP Holdings, LLC | Compositions and methods for treating fibromyalgia |
| US8747923B2 (en) | 2012-09-20 | 2014-06-10 | Quality Ip Holdings, Inc. | Methods for improving health in canines |
| US10894072B2 (en) | 2017-02-13 | 2021-01-19 | IP Quality Holdings, LLC | Compositions and methods for treating fibromyalgia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01308235A (en) * | 1988-06-03 | 1989-12-12 | Yamanouchi Pharmaceut Co Ltd | Human growth hormone for transnasal administration |
| KR100335564B1 (en) * | 1999-08-09 | 2002-05-08 | 성재갑 | Diat food composition for reducing body fat with growth hormone releasing enhancer |
| US20020002198A1 (en) * | 2000-04-17 | 2002-01-03 | Parr Tyler B. | Chemical synergy to elevate growth hormone release in vertebrates |
| IT1317043B1 (en) * | 2000-06-14 | 2003-05-26 | Sigma Tau Healthscience Spa | FOOD SUPPLEMENT ENHANCING THE ENERGETIC-MUSCULAR METABOLISM, INCLUDING AN ALCANOIL L-CARNITINE AND RIBOSE. |
| DE10036799A1 (en) * | 2000-07-28 | 2002-02-07 | Beiersdorf Ag | New treatment for hair and scalp |
-
2004
- 2004-06-25 WO PCT/CA2004/000953 patent/WO2004112511A2/en active Application Filing
- 2004-06-25 CA CA002529317A patent/CA2529317A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004112511A2 (en) | 2004-12-29 |
| WO2004112511A3 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6346264B1 (en) | Supplement for restoring growth hormone levels | |
| Cruz-Jentoft et al. | Nutritional strategies for maintaining muscle mass and strength from middle age to later life: A narrative review | |
| JP6335121B2 (en) | Facilitating muscle recovery after muscle atrophy caused by immobilization | |
| US20220072096A1 (en) | Whey protein micelles against muscle atrophy and sarcopenia | |
| US20080317886A1 (en) | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness | |
| BR112013000446B1 (en) | use of vitamin d and l-leucine in its free form for the manufacture of a medicament for the prevention and / or treatment of a disease or condition involving muscle wasting in an adult mammal | |
| JP7434155B2 (en) | Compositions and methods using combinations of autophagy inducers and high protein for induction of autophagy | |
| CA2600550A1 (en) | Composition and method for modulating hydrogen ion physiology | |
| EP3021690B1 (en) | Muscle preservation in overweight or obese adult during weight loss program | |
| CA2529317A1 (en) | Supplement for restoring growth hormone levels | |
| JP2019182881A (en) | Composition for preventing or improving peripheral neuropathy | |
| JP7410025B2 (en) | Compositions and methods of using high protein for induction of autophagy | |
| US20160095894A1 (en) | Dietetic multi-component system | |
| CA3121082A1 (en) | Supplement including gamma-aminobutyric acid for restoring growth hormone levels | |
| US20150045432A1 (en) | Dietary supplement comprising amino acids in a palatable liquid formulation that promotes restful sleep, recovery from stress and exercise and strengthens the immune system | |
| CA3081988A1 (en) | Supplement including gamma-aminobutyric acid for restoring growth hormone levels | |
| WO2019146735A1 (en) | Composition for preventing or improving nociceptive pain | |
| CA3216989A1 (en) | Nutritional compositions for preserving muscle mass | |
| RU2021111065A (en) | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDRIBOZIDE OR NAD+ PRECURSOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |